IXICO PLC lands £800,000 deal with Huntington
Neuroimaging pioneer IXICO PLC (AIM:IXI, OTC:PHYOF) says it has won a contract with an unnamed biotech worth around £800,000 to provide its expertise in assessing the progression of Huntington’s disease.
Specifically, it will support a global observational study to assess participants for early disease detection using its artificial intelligence-based data analysis, machine learning techniques and TrialTracker platform.
Chief Executive Giulio Cerroni said: “With no current cure for Huntington’s disease, nor interventions that slow disease progression, HD is a devastating rare neurological disease with significant unmet medical needs. .
“We are excited to further expand our customer base and support the identification of new knowledge about this rare and difficult neurodegenerative disease.”
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that nothing posted on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is…
In exchange for the publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Site Content, the Company receives from said issuer…
FOR OUR FULL DISCLAIMER, CLICK HERE